Global Embolotherapy Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2033

Global Embolotherapy Market Segmentation, By Product (Embolic Agents and Support Devices), Disease Indication (Cancer, Peripheral Vascular Disease, Neurological Diseases, Urological and Nephrological Disorders and Gastrointestinal Disorders), Procedure (Trans catheter Arterial Embolization (TAE), Trans catheter Arterial Radio embolization (TARE)/ Selective Internal Radiation Therapy (SIRT) and Trans arterial Chemoembolization), End User (Hospitals and Clinics, Ambulatory Surgery Centres and Other End Users)- Industry Trends and Forecast to 2033

Embolotherapy Market Size

• The global embolotherapy market size was valued at USD 3.41 billion in 2025 and is expected to reach USD 6.31 billion by 2033, at a CAGR of 8.00% during the forecast period
• The market growth is largely fueled by the increasing prevalence of vascular diseases, advancements in minimally invasive procedures, and the rising adoption of image-guided embolization techniques in both developed and emerging healthcare settings
• Furthermore, growing preference for targeted, safe, and effective therapeutic interventions, along with expanding awareness among clinicians and patients about embolotherapy benefits, is positioning embolotherapy as a preferred treatment option. These converging factors are accelerating the adoption of embolotherapy solutions, thereby significantly driving the market's growth

Embolotherapy Market Analysis

• Embolotherapy, involving minimally invasive procedures to block or reduce blood flow to targeted areas, is increasingly vital in the treatment of vascular malformations, tumors, and hemorrhages in both interventional radiology and surgical settings due to its precision, safety, and effectiveness compared to conventional therapies
• The escalating demand for embolotherapy is primarily fueled by the rising prevalence of vascular diseases and cancers, advancements in imaging technologies for accurate procedure guidance, and growing clinician preference for minimally invasive, patient-friendly treatment options
• North America dominated the embolotherapy market with the largest revenue share of 38.9% in 2025, characterized by advanced healthcare infrastructure, high adoption of interventional radiology procedures, and a strong presence of key medical device manufacturers, with the U.S. witnessing significant growth in embolotherapy procedures driven by innovations in microcatheters, embolic agents, and image-guided technologies
• Asia-Pacific is expected to be the fastest-growing region in the embolotherapy market during the forecast period due to increasing healthcare expenditure, rising awareness of minimally invasive treatments, and expanding interventional radiology infrastructure across urban and semi-urban centers
• Embolic agents segment dominated the embolotherapy market with a market share of 45.8% in 2025, driven by continuous product innovations, expanding applications in tumor and vascular therapies, and their effectiveness in targeted occlusion with minimal complications

Report Scope and Embolotherapy Market Segmentation     

Embolotherapy Market Trends

Advancements in Image-Guided and Precision Embolization

• A significant and accelerating trend in the global embolotherapy market is the integration of advanced imaging modalities such as CT, MRI, and fluoroscopy with embolization procedures, enhancing procedural accuracy and patient outcomes

  • For instance, the Onyx Liquid Embolic System allows interventional radiologists to perform highly precise embolizations under real-time imaging guidance, minimizing damage to surrounding tissues

• Image-guided embolotherapy enables more targeted treatment of tumors, arteriovenous malformations, and hemorrhages, reducing complications and improving recovery times. For instance, the use of cone-beam CT in embolization procedures helps clinicians visualize vascular anatomy more clearly and optimize embolic agent delivery
• The seamless combination of advanced imaging and embolic materials facilitates minimally invasive procedures that can be customized to patient-specific anatomy and pathology
• This trend towards more precise, image-assisted embolization is fundamentally transforming clinical expectations and standards for interventional treatments. Consequently, companies such as Medtronic and Terumo are developing next-generation embolic devices compatible with high-resolution imaging systems
• The adoption of precision embolotherapy is increasing rapidly across both oncology and vascular intervention applications, as hospitals and specialty centers aim to improve patient safety and procedural efficacy
• Increasing integration of AI and software-based planning tools is enabling predictive modeling for embolization outcomes, helping clinicians select optimal embolic agents and procedural approaches
• Rising collaborations between device manufacturers and hospitals to develop customized embolization solutions are accelerating innovation and adoption in complex therapeutic areas

Embolotherapy Market Dynamics

Driver

Rising Prevalence of Vascular Diseases and Cancer

• The increasing incidence of vascular disorders, aneurysms, and tumors, coupled with a growing preference for minimally invasive treatments, is a key driver for embolotherapy market growth

  • For instance, in March 2025, Boston Scientific expanded its portfolio of microcatheters and embolic agents for targeted vascular interventions, aiming to address the rising burden of peripheral artery disease and liver tumors

• As clinicians increasingly seek safer and more effective alternatives to open surgery, embolotherapy offers precise occlusion of pathological vessels with reduced patient trauma
• Furthermore, the expanding awareness of embolotherapy benefits among healthcare professionals and patients is making it a preferred choice for interventional procedures
• The demand for efficient, targeted, and outpatient-friendly procedures is driving the adoption of advanced embolic materials and devices in both developed and emerging markets
• The growing focus on minimally invasive oncology interventions, particularly for liver and uterine tumors, is further fueling embolotherapy adoption
• Technological advancements in biodegradable and drug-eluting embolic agents are creating new therapeutic opportunities and expanding the clinical applications of embolotherapy

Restraint/Challenge

Procedure Complexity and High Device Costs

• The technical complexity of embolotherapy procedures, which require specialized training and expertise, poses a significant challenge to broader adoption, especially in smaller healthcare facilities

  • For instance, reports indicate that inadequate operator experience can increase procedure times and complication rates, limiting the accessibility of embolotherapy in low-resource settings

• In addition, the relatively high cost of advanced embolic agents, microcatheters, and imaging systems can restrict adoption among price-sensitive hospitals and healthcare systems

  • For instance, premium embolic products from companies such as Terumo and Merit Medical come with significant price tags, which may deter smaller clinics from investing in these solutions

• Overcoming these challenges through physician training programs, cost-effective product development, and streamlined procedure protocols will be crucial for sustained market growth
• Limited reimbursement policies for certain embolotherapy procedures in emerging markets can slow adoption and market expansion
• Regulatory hurdles related to device approvals and clinical trial requirements for novel embolic agents may delay product launches and affect market growth

Embolotherapy Market Scope

The market is segmented on the basis of product, disease indication, procedure, and end user.

• By Product

On the basis of product, the embolotherapy market is segmented into embolic agents and support devices. The embolic agents segment dominated the market with the largest revenue share of 45.8% in 2025, driven by their critical role in occluding targeted blood vessels with precision. Embolic agents such as microspheres, coils, and liquid embolics are widely used in oncology and vascular interventions, offering high efficacy and predictable outcomes. Their increasing adoption is fueled by ongoing innovations, including drug-eluting and biodegradable agents, which allow targeted therapy with minimal systemic effects. In addition, embolic agents are preferred due to their versatility across multiple indications such as cancer, neurological disorders, and gastrointestinal bleeding. Hospitals and specialty clinics often prioritize embolic agents due to their established clinical track record and ability to improve patient safety and procedure success rates.

The support devices segment is anticipated to witness the fastest CAGR from 2026 to 2033, driven by rising demand for advanced catheters, guidewires, microcatheters, and imaging-compatible devices that enhance procedural precision. Support devices improve the efficiency of embolization procedures, enabling clinicians to navigate complex vascular anatomies and deliver embolic agents more accurately. Technological advancements in these devices, such as improved flexibility, radiopacity, and integration with navigation systems, are further accelerating adoption in both developed and emerging markets. These devices also facilitate minimally invasive procedures, reducing patient recovery times and overall healthcare costs. Growing collaborations between device manufacturers and healthcare institutions are promoting the development of next-generation support tools. The segment is benefiting from increasing training programs and physician awareness about the importance of precision tools in embolotherapy.

• By Disease Indication

On the basis of disease indication, the market is segmented into cancer, peripheral vascular disease (PVD), neurological diseases, urological and nephrological disorders, and gastrointestinal disorders. The cancer segment dominated the market in 2025, driven by the high prevalence of liver, kidney, and uterine tumors and the rising adoption of minimally invasive embolization therapies for oncology treatment. Interventional radiologists prefer embolotherapy for tumor devascularization, palliative care, and as an adjunct to chemotherapy, offering better patient outcomes with fewer complications. Increasing awareness of embolotherapy as a safer alternative to open surgery and systemic chemotherapy is expanding its utilization in oncology centers globally. Growing research initiatives, clinical trials, and healthcare expenditure in oncology are further supporting the segment’s dominance. Hospitals and specialty clinics prioritize cancer embolotherapy due to its high success rates and targeted therapy benefits. Rising adoption of image-guided procedures enhances accuracy and reduces adverse effects in cancer patients.

The peripheral vascular disease segment is expected to witness the fastest growth during the forecast period, fueled by increasing cases of peripheral artery disease, diabetic vascular complications, and related cardiovascular disorders. Embolotherapy is gaining traction as a minimally invasive alternative for occluding diseased vessels and controlling abnormal blood flow. Early diagnosis, growing geriatric population, and integration of image-guided interventions in peripheral vascular procedures are further driving market expansion. The segment benefits from technological innovations in embolic agents and microcatheters designed for peripheral applications. Increasing awareness among physicians and patients about non-surgical treatment options is boosting adoption. Rising government initiatives for cardiovascular disease management are also supporting market growth.

• By Procedure

On the basis of procedure, the market is segmented into transcatheter arterial embolization (TAE), transcatheter arterial radioembolization (TARE)/selective internal radiation therapy (SIRT), and transarterial chemoembolization (TACE). The TACE segment dominated the market in 2025, driven by its widespread use in treating hepatocellular carcinoma and other liver tumors. TACE combines chemotherapy with embolic agents, allowing localized treatment, reduced systemic toxicity, and improved survival rates. Growing clinical evidence supporting its efficacy, along with increasing adoption in cancer treatment centers, supports its dominant position. Hospitals and specialty clinics prioritize TACE procedures due to their high success rates and ability to integrate with existing interventional radiology infrastructure. Increasing research and development activities to improve drug-eluting embolics and catheter systems further reinforce segment growth. The preference for outpatient and minimally invasive procedures is also contributing to higher adoption rates.

The TARE/SIRT segment is anticipated to witness the fastest CAGR from 2026 to 2033, owing to rising interest in radioembolization for liver and metastatic cancers. This procedure delivers radioactive microspheres directly to tumors, providing targeted therapy with minimal damage to surrounding tissues. Innovations in isotopes, personalized dosimetry, and improved imaging guidance are further accelerating adoption in oncology-focused healthcare facilities. Rising collaborations between hospitals and device manufacturers are improving accessibility and procedural efficiency. Increasing awareness about the advantages of SIRT over conventional therapies is driving its popularity. Regulatory approvals for novel radioembolic agents are also supporting the segment’s growth.

• By End User

On the basis of end user, the market is segmented into hospitals and clinics, ambulatory surgery centers (ASCs), and other end users. The hospitals and clinics segment dominated the market with the largest revenue share in 2025, due to well-established infrastructure, availability of trained interventional radiologists, and access to advanced imaging and embolic devices. Hospitals often serve as the primary treatment centers for complex vascular and oncology procedures, ensuring higher procedure volumes and adoption of cutting-edge embolotherapy solutions. The presence of multidisciplinary teams in hospitals enables integrated care and better patient management. Higher reimbursement support and insurance coverage for hospital-based procedures further drive adoption. Hospitals also invest in physician training programs and advanced equipment, reinforcing their dominant position in the market.

The ambulatory surgery centers segment is expected to witness the fastest growth during the forecast period, driven by increasing preference for outpatient minimally invasive procedures. ASCs offer cost-effective, efficient, and patient-friendly treatment options, making them attractive venues for embolotherapy procedures. The growing availability of portable imaging systems, combined with streamlined procedural workflows, supports the rapid adoption of embolotherapy in these centers. Expansion of ASCs in emerging markets is contributing to faster uptake. Increasing physician and patient awareness about the benefits of minimally invasive, same-day procedures is accelerating adoption. Technological advancements reducing procedure time and complexity further enhance segment growth.

Embolotherapy Market Regional Analysis

• North America dominated the embolotherapy market with the largest revenue share of 38.9% in 2025, characterized by advanced healthcare infrastructure, high adoption of interventional radiology procedures, and a strong presence of key medical device manufacturers, with the U.S. witnessing significant growth in embolotherapy procedures driven by innovations in microcatheters, embolic agents, and image-guided technologies
• Healthcare providers in the region prioritize minimally invasive procedures such as embolotherapy due to their precision, reduced patient recovery time, and lower complication rates compared to conventional surgery
• The widespread adoption is further supported by the presence of key medical device manufacturers, high healthcare expenditure, and a strong focus on research and development, establishing embolotherapy as a preferred treatment option for oncology and vascular interventions

U.S. Embolotherapy Market Insight

The U.S. embolotherapy market captured the largest revenue share of 79% in 2025 within North America, fueled by the widespread adoption of minimally invasive procedures and advanced interventional radiology infrastructure. Healthcare providers are increasingly prioritizing embolotherapy for oncology, vascular, and neurological interventions due to its precision, reduced complications, and shorter recovery times. The growing prevalence of liver, kidney, and uterine tumors, along with peripheral vascular diseases, is significantly driving procedural volumes. Furthermore, the increasing integration of image-guided systems, microcatheters, and embolic agents enhances procedural success rates. Government initiatives supporting minimally invasive therapies, combined with high healthcare expenditure, are also bolstering market growth.

Europe Embolotherapy Market Insight

The Europe embolotherapy market is projected to expand at a substantial CAGR throughout the forecast period, driven by rising incidences of cancer and vascular disorders and the growing adoption of minimally invasive interventions. Increasing urbanization, high healthcare spending, and government support for interventional procedures are fostering market growth. European healthcare providers are adopting embolotherapy for both oncology and vascular applications, supported by advanced imaging technologies and specialized physician training. The region is witnessing significant growth across hospitals and specialty clinics, with embolotherapy being integrated into treatment protocols for complex cases. In addition, rising awareness of patient safety and reduced hospitalization time is encouraging adoption.

U.K. Embolotherapy Market Insight

The U.K. embolotherapy market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increasing demand for minimally invasive therapies and advanced treatment options for cancer and vascular diseases. Concerns regarding procedural safety, patient recovery, and efficacy are encouraging hospitals and specialty clinics to adopt embolotherapy solutions. The country’s well-established healthcare infrastructure, along with training programs for interventional radiologists, is expected to continue supporting market expansion. Increasing clinical evidence and favorable reimbursement policies further stimulate adoption. Growing awareness among patients about less invasive treatment options is also contributing to market growth.

Germany Embolotherapy Market Insight

The Germany embolotherapy market is expected to expand at a considerable CAGR during the forecast period, fueled by rising awareness of minimally invasive procedures and the availability of technologically advanced embolic agents and support devices. Germany’s well-developed healthcare infrastructure, combined with strong emphasis on research and innovation, promotes the adoption of embolotherapy across oncology and vascular interventions. Hospitals and specialty clinics are increasingly integrating embolotherapy into treatment protocols for complex vascular and tumor cases. Moreover, growing investments in advanced imaging technologies, patient education, and clinical training are further supporting market expansion. The demand for precision therapies and improved patient outcomes aligns with local healthcare priorities, enhancing market growth.

Asia-Pacific Embolotherapy Market Insight

The Asia-Pacific embolotherapy market is poised to grow at the fastest CAGR of 25% during the forecast period of 2026 to 2033, driven by increasing prevalence of cancer and vascular disorders, rising healthcare expenditure, and technological advancements in countries such as China, Japan, and India. The region's growing inclination towards minimally invasive interventions, supported by government initiatives promoting advanced medical procedures, is driving adoption. Expansion of hospitals and specialty clinics with modern interventional radiology facilities is accelerating uptake. In addition, rising awareness among physicians and patients about the benefits of embolotherapy, coupled with availability of cost-effective devices, is contributing to rapid market growth. Emerging markets in APAC are also witnessing increasing collaborations with global device manufacturers, enhancing access to innovative embolotherapy solutions.

Japan Embolotherapy Market Insight

The Japan embolotherapy market is gaining momentum due to the country’s advanced healthcare infrastructure, high prevalence of vascular and oncological conditions, and focus on minimally invasive interventions. Japanese hospitals and specialty clinics are increasingly adopting embolotherapy for tumor management, aneurysm treatment, and peripheral vascular diseases. Integration with advanced imaging modalities and navigation systems is driving procedural accuracy and outcomes. Moreover, government initiatives promoting innovative therapies and aging population concerns are such asly to spur demand for safer, outpatient-friendly procedures. The growing focus on precision medicine and specialized interventional training programs is further fueling market growth.

India Embolotherapy Market Insight

The India embolotherapy market accounted for the largest market revenue share in Asia-Pacific in 2025, attributed to the country’s rising incidence of cancer and vascular disorders, expanding healthcare infrastructure, and growing awareness of minimally invasive treatments. India’s increasing number of hospitals and specialty clinics equipped with interventional radiology facilities is accelerating the adoption of embolotherapy procedures. Government initiatives supporting advanced medical technologies and affordable healthcare are further propelling growth. Rising awareness among physicians and patients about procedure safety, efficacy, and reduced hospitalization is boosting market demand. In addition, cost-effective embolic agents and support devices from both domestic and international manufacturers are increasing accessibility for a broader patient base.

Embolotherapy Market Share

The Embolotherapy industry is primarily led by well-established companies, including:

• Boston Scientific Corporation (U.S.)
• Merit Medical Systems (U.S.)
• Terumo Corporation (Japan)
• Medtronic (Ireland)
• Johnson & Johnson Services, Inc. (U.S.)
• Stryker (U.S.)
• Cook (U.S.)
• Penumbra, Inc. (U.S.)
• Sirtex Medical (Australia)
• Abbott (U.S.)
• Balt Group (France)
• Kaneka Corporation (Japan)
• Meril Life Sciences Pvt. Ltd. (India)
• Acandis GmbH (Germany)
• Varian Medical Systems (U.S.)
• Shape Memory Medical, Inc. (U.S.)
• Artio Medical, Inc. (U.S.)
• Rapid Medical (U.S.)
• Microport Scientific Corporation (China)
• Embolx Inc. (U.S.)

What are the Recent Developments in Global Embolotherapy Market?

• In July 2025, Arsenal Medical reported results from the clinical trial EMBO-02 Trial, showing that their next‑generation liquid embolic NeoCast achieved complete target‑vessel occlusion without non‑target embolization and resulted in rapid resorption of chronic subdural hematoma (cSDH), with no pain during injection marking a major advance in distal‑penetration, non‑adhesive embolic materials
• In June 2025, Embolization, Inc. received FDA 510(k) clearance for its novel non‑metal coil device, the NED Vascular Coil, a polymer‑based coil designed for arterial and venous embolization in peripheral vasculature offering reduced imaging artifacts and potentially replacing conventional metal coils in many applications
• In January 2025, Instylla, Inc. announced that its Tembo Embolic System a bioresorbable embolic agent comprised of irregular, dry‑gelatin particles (85–255 µm) received 510(k) clearance from the U.S. Food and Drug Administration (FDA), enabling its use for embolization of hypervascular tumors and peripheral vascular vessels
• In July 2024, Arsenal Medical announced that in the first‑in‑human trial EMBO-01 Trial of NeoCast for hypervascular brain tumors, the agent met primary safety and feasibility endpoints, achieved 88% tumor devascularization, and enabled complete resection with good vessel occlusion highlighting its potential as a more effective liquid embolic
• In May 2024, Merit Medical Systems announced FDA 510(k) clearance and launch of its Siege Vascular Plug and Bearing nsPVA Express Prefilled Syringe expanding its embolics portfolio with a rapidly occluding vascular plug and a pre‑filled PVA microsphere delivery system to simplify embolization procedures.

SKU-46182